247 related articles for article (PubMed ID: 21660516)
1. Biosensor-based small molecule fragment screening with biolayer interferometry.
Wartchow CA; Podlaski F; Li S; Rowan K; Zhang X; Mark D; Huang KS
J Comput Aided Mol Des; 2011 Jul; 25(7):669-76. PubMed ID: 21660516
[TBL] [Abstract][Full Text] [Related]
2. Biolayer interferometry provides a robust method for detecting DNA binding small molecules in microbial extracts.
Overacker RD; Plitzko B; Loesgen S
Anal Bioanal Chem; 2021 Feb; 413(4):1159-1171. PubMed ID: 33236226
[TBL] [Abstract][Full Text] [Related]
3. Biolayer interferometry for DNA-protein interactions.
Barrows JK; Van Dyke MW
PLoS One; 2022; 17(2):e0263322. PubMed ID: 35108320
[TBL] [Abstract][Full Text] [Related]
4. [Fragment screening using surface plasmon resonance optical biosensor technology].
Miura T
Yakugaku Zasshi; 2010 Mar; 130(3):341-8. PubMed ID: 20190519
[TBL] [Abstract][Full Text] [Related]
5. Applications of Surface Plasmon Resonance and Biolayer Interferometry for Virus-Ligand Binding.
Murali S; Rustandi RR; Zheng X; Payne A; Shang L
Viruses; 2022 Mar; 14(4):. PubMed ID: 35458446
[TBL] [Abstract][Full Text] [Related]
6. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
[TBL] [Abstract][Full Text] [Related]
7. Multiplexed experimental strategies for fragment library screening against challenging drug targets using SPR biosensors.
FitzGerald EA; Vagrys D; Opassi G; Klein HF; Hamilton DJ; Talibov VO; Abramsson M; Moberg A; Lindgren MT; Holmgren C; Davis B; O'Brien P; Wijtmans M; Hubbard RE; de Esch IJP; Danielson UH
SLAS Discov; 2024 Jan; 29(1):40-51. PubMed ID: 37714432
[TBL] [Abstract][Full Text] [Related]
8. Label-free detection of biomolecular interactions using BioLayer interferometry for kinetic characterization.
Concepcion J; Witte K; Wartchow C; Choo S; Yao D; Persson H; Wei J; Li P; Heidecker B; Ma W; Varma R; Zhao LS; Perillat D; Carricato G; Recknor M; Du K; Ho H; Ellis T; Gamez J; Howes M; Phi-Wilson J; Lockard S; Zuk R; Tan H
Comb Chem High Throughput Screen; 2009 Sep; 12(8):791-800. PubMed ID: 19758119
[TBL] [Abstract][Full Text] [Related]
9. A single-step, high throughput, and highly reproducible method for measuring IgM quantity and avidity directly from fish serum via biolayer interferometry (BLI).
Li A; Harris RJ; Fry BG; Barnes AC
Fish Shellfish Immunol; 2021 Dec; 119():231-237. PubMed ID: 34626789
[TBL] [Abstract][Full Text] [Related]
10. Label free fragment screening using surface plasmon resonance as a tool for fragment finding - analyzing parkin, a difficult CNS target.
Regnström K; Yan J; Nguyen L; Callaway K; Yang Y; Diep L; Xing W; Adhikari A; Beroza P; Hom RK; Riley B; Rudolph D; Jobling MF; Baker J; Johnston J; Konradi A; Bova MP; Artis DR
PLoS One; 2013; 8(7):e66879. PubMed ID: 23861750
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of fragment screening methods on the p38α kinase: new methods, new insights.
Pollack SJ; Beyer KS; Lock C; Müller I; Sheppard D; Lipkin M; Hardick D; Blurton P; Leonard PM; Hubbard PA; Todd D; Richardson CM; Ahrens T; Baader M; Hafenbradl DO; Hilyard K; Bürli RW
J Comput Aided Mol Des; 2011 Jul; 25(7):677-87. PubMed ID: 21732248
[TBL] [Abstract][Full Text] [Related]
12. SPR-based fragment screening: advantages and applications.
Neumann T; Junker HD; Schmidt K; Sekul R
Curr Top Med Chem; 2007; 7(16):1630-42. PubMed ID: 17979772
[TBL] [Abstract][Full Text] [Related]
13. Determination of High-affinity Antibody-antigen Binding Kinetics Using Four Biosensor Platforms.
Yang D; Singh A; Wu H; Kroe-Barrett R
J Vis Exp; 2017 Apr; (122):. PubMed ID: 28448040
[TBL] [Abstract][Full Text] [Related]
14. Protein-Protein Binding Kinetics by Biolayer Interferometry.
Santos-López J; Gómez S; Fernández FJ; Vega MC
Adv Exp Med Biol; 2024; 3234():73-88. PubMed ID: 38507201
[TBL] [Abstract][Full Text] [Related]
15. BLI-Based Functional Assay in Phage Display Benefits the Development of a PD-L1-Targeting Therapeutic Antibody.
Choi JR; Kim MJ; Tae N; Wi TM; Kim SH; Lee ES; Kim DH
Viruses; 2020 Jun; 12(6):. PubMed ID: 32630442
[TBL] [Abstract][Full Text] [Related]
16. From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance.
Giannetti AM
Methods Enzymol; 2011; 493():169-218. PubMed ID: 21371592
[TBL] [Abstract][Full Text] [Related]
17. Enzyme-linked, aptamer-based, competitive biolayer interferometry biosensor for palytoxin.
Gao S; Zheng X; Hu B; Sun M; Wu J; Jiao B; Wang L
Biosens Bioelectron; 2017 Mar; 89(Pt 2):952-958. PubMed ID: 27816587
[TBL] [Abstract][Full Text] [Related]
18. Measuring protein-protein and protein-nucleic Acid interactions by biolayer interferometry.
Sultana A; Lee JE
Curr Protoc Protein Sci; 2015 Feb; 79():19.25.1-19.25.26. PubMed ID: 25640894
[TBL] [Abstract][Full Text] [Related]
19. Experimental validation of a fragment library for lead discovery using SPR biosensor technology.
Elinder M; Geitmann M; Gossas T; Källblad P; Winquist J; Nordström H; Hämäläinen M; Danielson UH
J Biomol Screen; 2011 Jan; 16(1):15-25. PubMed ID: 21149860
[TBL] [Abstract][Full Text] [Related]
20. Emerging role of surface plasmon resonance in fragment-based drug discovery.
Navratilova I; Hopkins AL
Future Med Chem; 2011 Oct; 3(14):1809-20. PubMed ID: 22004086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
